GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Renascience 4889.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

802

+3.62%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥68.6m

FY2020FY2026

Net income

−¥301.3m

FY2020FY2026

Free cash flow

−¥291.3m

FY2020FY2026

Shareholders' equity

¥3.32bn

FY2020FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue¥68.6m¥132.7m¥194.2m¥100.5m¥139.3m¥209.8m¥72.0m
Research and development—¥132.9m¥236.0m¥235.0m¥82.7m¥81.4m¥26.0m
Operating income−¥356.9m−¥178.8m−¥252.3m−¥333.9m−¥222.2m−¥92.3m−¥183.0m
Net income−¥301.3m¥113.4m−¥258.3m−¥335.8m−¥254.3m−¥100.1m−¥184.0m
Diluted earnings per share-21.878.88-20.32-26.42-20.00-7.26-13.36

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Total assets¥3.50bn¥1.87bn¥2.09bn¥2.27bn¥2.44bn¥1.07bn¥1.01bn
Cash and short-term investments¥3.40bn¥1.80bn¥2.03bn¥2.21bn¥2.39bn¥1.03bn¥981.0m
Total liabilities¥180.6m¥151.2m¥482.1m¥409.8m¥237.2m¥505.1m¥391.1m
Debt——¥356.1m¥309.6m¥199.2m¥475.6m¥380.0m
Shareholders' equity¥3.32bn¥1.72bn¥1.61bn¥1.87bn¥2.20bn¥561.5m¥621.6m
Shares outstanding14m13m13m13m13m14m14m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−¥291.3m−¥176.3m−¥230.5m−¥284.6m−¥230.5m−¥89.3m−¥178.3m
Capital spending—−¥799,000−¥1.6m−¥2.2m−¥1.2m−¥1.0m—
Free cash flow−¥291.3m−¥177.1m−¥232.1m−¥286.9m−¥231.7m−¥90.3m−¥178.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥10.0m¥28.6m¥30.0m—¥10.0m¥66.9m¥10.0m¥15.7m
Operating income−¥82.1m−¥101.7m−¥66.7m−¥86.2m−¥102.3m−¥38.9m−¥49.0m−¥54.5m
Net income−¥82.0m−¥83.0m−¥66.6m−¥84.9m−¥66.9m−¥40.7m¥226.0m−¥56.0m
Diluted earnings per share-5.95-6.02-5.22-6.65-5.24-3.1917.78-4.41
Total assets¥3.29bn¥3.50bn¥2.56bn¥1.68bn¥1.73bn¥1.87bn¥1.91bn¥1.96bn
Cash and short-term investments¥3.20bn¥3.40bn¥2.42bn¥1.57bn¥1.67bn¥1.80bn¥1.84bn¥1.91bn
Debt———————¥365.6m
Shareholders' equity¥3.24bn¥3.32bn¥2.42bn¥1.57bn¥1.65bn¥1.72bn¥1.76bn¥1.53bn

Financial ratios

Data as of 24 Sept 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-520.6%-134.8%-130.0%-332.1%-159.5%-44.0%—
Net margin-439.5%85.5%-133.0%-334.0%-182.5%-47.7%—
Return on equity-9.1%6.6%-16.1%-18.0%-11.6%-17.8%—
Return on assets-8.6%6.1%-12.4%-14.8%-10.4%-9.4%—
Free cash flow yield-1.8%-1.2%-1.5%-1.9%-1.5%——
Revenue growth-48.3%-31.7%93.1%-27.8%-33.6%191.4%—
Earnings growth-365.6%-143.9%-23.1%32.1%154.2%-45.6%—
Current ratio19.40x12.38x16.56x22.64x64.00x35.41x—
Debt to equity—0.00x0.22x0.17x0.09x0.85x0.61x
Equity ratio94.8%91.9%76.9%82.0%90.3%52.6%—
Interest coverage————-41.41x-12.29x-535.52x
R&D as a share of sales—100.1%121.5%233.7%59.4%38.8%36.1%
Buybacks as a share of market value-7.9%-0.4%0.0%0.0%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-12.0%-18.9%—
Operating income2.2%31.1%—
Net income-3.6%24.7%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-266.2%-226.2%-170.0%—
Net margin-93.3%-157.7%-134.5%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings-42.3159.4-14.6-16.4-18.4-94.0
Price to sales186.1136.319.454.945.348.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.